146 related articles for article (PubMed ID: 19369429)
1. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes.
Hemmingsen B; Lund SS; Wetterslev J; Vaag A
Eur J Endocrinol; 2009 Jul; 161(1):1-9. PubMed ID: 19369429
[TBL] [Abstract][Full Text] [Related]
2. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications.
Abdul-Ghani MA; Jayyousi A; DeFronzo RA; Asaad N; Al-Suwaidi J
Curr Vasc Pharmacol; 2019; 17(2):153-163. PubMed ID: 29032755
[TBL] [Abstract][Full Text] [Related]
5. Diabetes and branched-chain amino acids: What is the link?
Bloomgarden Z
J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
7. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
[TBL] [Abstract][Full Text] [Related]
8. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
9. A review on cardiovascular effects of newer hypoglycaemic medications.
Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
[TBL] [Abstract][Full Text] [Related]
10. [Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus].
Schumm-Draeger PM
MMW Fortschr Med; 2005 Apr; 147(17):32-4, 36. PubMed ID: 15903057
[TBL] [Abstract][Full Text] [Related]
11. Diabetes Mellitus and Its Cardiovascular Complications: New Insights into an Old Disease.
Sardu C; De Lucia C; Wallner M; Santulli G
J Diabetes Res; 2019; 2019():1905194. PubMed ID: 31236416
[No Abstract] [Full Text] [Related]
12. Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents.
Granberry MC; Fonseca VA
Am J Cardiovasc Drugs; 2005; 5(3):201-9. PubMed ID: 15901207
[TBL] [Abstract][Full Text] [Related]
13. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries.
Mosenzon O; Alguwaihes A; Leon JLA; Bayram F; Darmon P; Davis TME; Dieuzeide G; Eriksen KT; Hong T; Kaltoft MS; Lengyel C; Rhee NA; Russo GT; Shirabe S; Urbancova K; Vencio S;
Cardiovasc Diabetol; 2021 Jul; 20(1):154. PubMed ID: 34315481
[TBL] [Abstract][Full Text] [Related]
14. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
[TBL] [Abstract][Full Text] [Related]
15. Metformin: diamonds are forever.
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
[TBL] [Abstract][Full Text] [Related]
16. Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.
Sullivan D; Forder P; Simes J; Whiting M; Kritharides L; Merrifield A; Donoghoe M; Colman PG; Graham N; Haapamäki H; Keech A;
Diabetes Res Clin Pract; 2011 Nov; 94(2):284-90. PubMed ID: 21862166
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
Zimmet P; Collier G
Drugs; 1999; 58 Suppl 1():21-8; discussion 75-82. PubMed ID: 10576521
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention.
Henry RR
Am J Med; 1998 Jul; 105(1A):20S-26S. PubMed ID: 9707264
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral hypoglycemic agents on platelet function.
Papazafiropoulou A; Papanas N; Pappas S; Maltezos E; Mikhailidis DP
J Diabetes Complications; 2015 Aug; 29(6):846-51. PubMed ID: 26026848
[TBL] [Abstract][Full Text] [Related]
20. Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.
Green JB
Postgrad Med; 2014 May; 126(3):190-204. PubMed ID: 24918803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
